Organoids to study immune functions, immunological diseases and immunotherapy
This spring, on an earnings call with Pepsi, the daughter of an analystwho was with her dad for Bring Your Kid to Work Dayhad one question for the CEO of the beverage giant: So what do you think about the launch of GLP-1 oral medications coming to market next year? If only the Gila monster could talk
Ro emphasizes convenient access to clinicians and prescriptions, focusing primarily on medication management and medical oversight, with less emphasis on long-term habit support
Find articles by Holter, M
Until the pricing or coverage picture changes fundamentally, this market will keep growing at the top
This suggests GLP-1 drugs may act earlier in the addiction cycle, reducing cue reactivity and craving, rather than reducing reward after use